HARBIN, China, June 23 /Xinhua-PRNewswire/ -- Pingchuan Pharmaceutical Inc. (“PINGCHUAN”) announced today that PINGCHUAN signed a market research consignment agreement with Moscow Sing Sing Co. Ltd (“SING SING”).
According to the agreement, SING SING authorized PINGCHUAN as its exclusive partner to conduct market researches for business projects in P. R. China (exclude Hong Kong, Macao and Taiwan). PINGCHUAN promises to accomplish commercial market researches and deliver business plans for SING SING within the valid period of the agreement. The co-operation with SING SING, will bring in revenue of USD 200,000 for PINGCHUAN.
“I can speak a little Chinese and many of my clients are engaged in commercial activities related to the Chinese market,” said Mr. Kanstantin Ivanovic, the Chairman and General Manager of SING SING. “With the commercial research reports provided by PINGCHUAN, we are able to obtain the Chinese market intelligence, from professional, accurate and trustful channels.” Hu ZhanWu, Chairman and President of Pingchuan Pharmaceutical Inc. commented, “We are delighted to enter into alliance with SING SING. We believe this is a mutually benefit arrangement that is very likely to become a constant operative program under both PINGCHUAN and SING SING.”
About Pingchuan Pharmaceutical Inc.
Pingchuan Pharmaceutical Inc. (“PINGCHUAN”) is a modernized pharmaceutical manufacturer with first-class medical R&D ability, pioneered medicine products, and well-established marketing network. Since its establishment, PINGCHUAN has focused its businesses on diabetes medicine and its medical products. The products of PINGCHUAN include health care products, varieties of medicine, as well as medical apparatus. Kang Da Glycosuria Capsule is a successful product of PINGCHUAN for treating diabetes, which was first developed in 1998 and introduced to the market in 2001. PINGCHUAN has well-established marketing network and sale branches, which include about 180,000 retail pharmacies/drugstores across China, agency network in major cities like Beijing, Shanghai, Guangzhou, and Xi’an, special counter sale at drug chain stores in key regions, residence community clinic sale and promotion, as well as internet marketing through the company’s website. The marketing network of PINGCHUAN covers more than 50% districts of China and exports to US, Japan, Russia, and south-eastern Asia.
About Moscow Sing Sing Co. Ltd.
Moscow Sing Sing Co. Ltd was established in 1988, with the registered capital approximately equal to USD 200,000 nowadays. The company produced desktop computers, correlative supplies and equipment room building. After the desegregation of the Former Soviet Union, it gradually shifted its core businesses to the area of network building, software development and international commerce consultation.
Safe Harbor
Information in this news release or on this website may contain statements about future expectations, plans, prospects or performance of Pingchuan Pharmaceutical Inc. that constitute forward-looking statements for purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. The words or phrases “can be,” “expects,” “may affect,” “believed,” “estimate,” “project,” and similar words and phrases are intended to identify such forward-looking statements. Pingchuan Pharmaceutical Inc. cautions you that any forward-looking information provided by or on behalf of Pingchuan Pharmaceutical Inc. is not a guarantee of future performance. None of the information on this website constitutes an offer to sell securities or investment advice of any kind, and visitors should not base their investment decisions on information contained in this website. Pingchuan Pharmaceutical Inc.'s actual results may differ materially from those anticipated in such forward-looking statements as a result of various important factors, some of which are beyond Pingchuan Pharmaceutical Inc.'s control. In addition to those discussed in Pingchuan Pharmaceutical Inc.'s press releases, public filings, and statements by Pingchuan Pharmaceutical Inc.'s management, including, but not limited to, Pingchuan Pharmaceutical Inc.'s estimate of the sufficiency of its existing capital resources, Pingchuan Pharmaceutical Inc.'s ability to raise additional capital to fund future operations, Pingchuan Pharmaceutical Inc.'s ability to repay its existing indebtedness, the uncertainties involved in estimating market opportunities and, in identifying contracts which match Pingchuan Pharmaceutical Inc.'s capability to be awarded contracts. All such forward-looking statements are current only as of the date on which such statements were made. Pingchuan Pharmaceutical Inc. does not undertake any obligation to publicly update any forward-looking statement to reflect events or circumstances after the date on which any such statement is made or to reflect the occurrence of unanticipated events.
Pingchuan Pharmaceutical Inc.
CONTACT: Xiao Yi of Pingchuan Pharmaceutical Inc., 13601383001,BJ_xiaoyi@yahoo.com.cn
